A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)

NCT07582315 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

538

Enrollment

INDUSTRY

Sponsor class

Conditions

Biliary Tract Cancer

Interventions

DRUG: BL-B01D1
DRUG: Oxaliplatin
DRUG: Calcium levofolinate
DRUG: Fluorouracil
DRUG: Irinotecan Hydrochloride Liposome
DRUG: Irinotecan Hydrochloride
DRUG: Capecitabine

Sponsor

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborators

[object Object]